InvestSMART

Saluda Medical, Inc. (ASX:SLD)

ALERT: Price-sensitive ASX Announcement for SLD
Current share price for SLD : $0.620 0.21 (51.22%)+
Announcement
Release
29 Jul 2026 8:31AM
Price at Release
$0.410
Full Release
download
Summary
Saluda Medical, Inc. reported strong financial results for Q4 FY26, surpassing its full-year revenue guidance with US$90.2 million, reflecting a 28% growth over the previous year. The company achieved US$27.0 million in global revenue for the quarter, driven by significant growth in both US and international markets. The approval of the CAP24™ paddle lead by the FDA expanded Saluda's product offerings. The company also succeeded in expanding its US sales force and bolstering physician engagement, contributing to increased revenues and patient implants. Despite a strategic reduction in non-commercial staff to reduce future expenses, Saluda maintained a robust cash position at the end of the quarter.
Key Points
  • Saluda Medical exceeded FY26 revenue guidance, achieving US$90.2 million, a 28% year-over-year growth.
  • Q4 FY26 global revenue reached US$27.0 million, marking a 43% increase compared to the previous corresponding period.
  • FDA approved the CAP24™ paddle lead, expanding the Evoke® System portfolio for Saluda Medical.
  • US revenues increased by 45% in Q4, with a 50% rise in implanted patients and substantial growth in physician engagement.
  • International revenues grew by 39% driven by strong demand in Europe and Australia.
  • Saluda expanded its US sales force to 161 representatives, exceeding their target for FY26.
  • The company executed a phased reduction in force to optimize future operating expenses.
  • Saluda ended Q4 FY26 with US$116.4 million in cash and available funding of US$141.4 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.